Xconomy: Amag Rebounds from FDA Handwringing, Looks To Stock Pipeline Through Acquisitions
Summary
Amag Rebounds from FDA Handwringing, Looks To Stock Pipeline Through Acquisitions (Page 2 of 2) the broad market—women with heavy menstrual bleeding or post-pregnancy anemia, cancer patients, and so on,” Pereira says.His only management experience had come from serving as CEO of the physicians’ group at Tufts New England Medical Center, but he knew what Amag needed to do to position itself as a drug developer.It’s like everything else in life: success begets success.” With its product now on the market and the safety saga a near memory, Amag is now shopping for other molecules to bolster its pipeline.Pereira declines to specify what types of drugs Amag is looking to acquire or what its timeline for such a move might be, except to say “We are looking at candidates right now.” The basic idea, he says, is to bring in products that Amag could ultimately market with its existing salesforce, which calls on physicians in nephrology, hematology, and oncology.Zieziula responds by pointing out that like any publicly held company, Amag is beholden to its shareholders and would have to seriously consider any buyout offers.